2 FTSE 100 dividend stocks to buy in September

Dividends can play an important role in an investment portfolio. Here, Edward Sheldon highlights two FTSE 100 dividend stocks he likes in early September.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 dividend stocks play an important role in my investment portfolio. Not only do they provide me with regular passive income but they also add a degree of portfolio stability.

Here, I’m going to highlight two FTSE 100 dividend stocks I see as attractive at present. I’d be happy to buy both as we begin September.

A top FTSE 100 dividend stock

One dividend stock that strikes me as a ‘buy’ right now is Smith & Nephew (LSE: SN). It’s a leading healthcare company specialising in orthopaedic implants and advanced wound management solutions. Its share price has pulled back recently and I think this has provided a great buying opportunity.

Smith & Nephew struggled during Covid-19 last year due to the fact that so many elective medical procedures had to be postponed. However, it’s now making a strong recovery. For the six-month period to 3 July, revenue was up 28%. For the full year, the group expects revenue growth of 10-13% (I think there’s a good chance it will exceed this). If revenues and profits continue to rebound, its share price should too.

Smith & Nephew isn’t the highest-yielding stock in the lead index. Currently, the prospective yield here is only around 1.8%. I still see appeal in that yield however. This is a company with an excellent long-term dividend growth track record and I expect its dividend payouts to continue rising over the long term as profits expand.

One risk to consider here is further Covid-19 setbacks. If the Delta variant results in a high level of hospitalisations, Smith & Nephew could be disrupted again.

But I’m comfortable with the risks. With the stock trading at 19 times next year’s earnings (versus 27 times for US rival Stryker), I see value here.

Attractive dividend yield

Another FTSE 100 dividend stock I like the look of right now is Unilever (LSE: ULVR). It’s a leading consumer goods giant that owns a wide range of brands such as Dove, Domestos, and Hellmann’s. Its share price has also pulled back recently (mainly due to concerns over higher input costs) and I see this as a good opportunity to build a position.

Unilever’s recent half-year results were quite solid, in my view. For the six months to 30 June, sales were up 5.4%. E-commerce sales jumped 50% while sales in the emerging markets were up 8.3%. These figures suggest to me the company’s heading in the right direction, despite the fact that inflationary pressures are impacting profits.

At present, Unilever shares offer a prospective dividend yield of around 3.7%. That yield’s very attractive, in my view. By contrast, the median forward-looking dividend yield across the FTSE 100 index is around 3.2%. It’s worth pointing out that a yield of 3.7% is quite high for Unilever.

The key risk here, in my view, is that inflation could continue to be a problem for the company. It’s worth noting that last week, analysts at JP Morgan downgraded the stock to ‘underweight’ on the back of inflation concerns.

The contrarian in me sees an opportunity here however. With the stock currently a little bit out of favour and trading on a forward-looking P/E ratio of under 19, I think it’s a good time to be buying.

JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. Edward Sheldon owns shares of Smith & Nephew and Unilever. The Motley Fool UK has recommended Smith & Nephew and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Grattan Bridge in Dublin, Ireland, on the River Liffey at sunset
Investing Articles

Should I buy the maker of Guinness for snowballing passive income?

Ben McPoland is hunting for a new UK dividend stock to increase his passive income. Does this FTSE 100 booze…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

A £20,000 ISA invested in red-hot BP and Shell shares 1 year ago is now worth…

Investing in BP and Shell shares has paid off lately, with bags of share price growth and dividends. But are…

Read more »

Young woman holding up three fingers
Investing Articles

3 FTSE 100 shares I think look undervalued heading into May

This trio of FTSE 100 dogs have been moving in the opposite direction from the flagship blue-chip index so far…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

As the Lloyds share price falls while profits rise, is it time to dump?

Investors might be getting cold feet over the Lloyds share price, as a better-than-expected quarter still resulted in a decline.

Read more »

Buffett at the BRK AGM
Investing Articles

Might it make sense to ‘go away’ from the stock market in May?

Drawing on Warren Buffett and Charlie Munger's long-term investing approach, this writer explains why he won't be ignoring the stock…

Read more »

British union jack flag and Parliament house at city of Westminster in the background
Investing Articles

Up 1,000% in 5 years, but the UK government could send Rolls-Royce shares even higher

Rolls-Royce shares have been in the doldrums in the past few weeks. Is the long-term picture still as bright as…

Read more »

Investing Articles

As GSK shares fall 5% on Q1 news, is this a buying opportunity?

GSK reinforced its upbeat guidance for the year ahead in a Q1 update, after an impressive 2025, but the shares…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Meet the FTSE 250 stock that has left Rolls-Royce, Nvidia and BP in the dust

This FTSE 250 stock has risen more than 900% in the past year, including a 19% jump today. What's behind…

Read more »